Rhumbline Advisers boosted its position in Qiagen N.V. (NASDAQ:QGEN) by 4.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,769 shares of the company’s stock after buying an additional 9,208 shares during the period. Rhumbline Advisers owned 0.09% of Qiagen N.V. worth $7,268,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. M&T Bank Corp purchased a new stake in Qiagen N.V. during the first quarter worth about $230,000. Envestnet Asset Management Inc. purchased a new stake in Qiagen N.V. during the first quarter worth about $667,000. Parametric Portfolio Associates LLC increased its stake in Qiagen N.V. by 4.1% in the first quarter. Parametric Portfolio Associates LLC now owns 651,832 shares of the company’s stock worth $18,884,000 after buying an additional 25,582 shares in the last quarter. Karp Capital Management Corp purchased a new stake in Qiagen N.V. during the first quarter worth about $5,862,000. Finally, Bank of New York Mellon Corp increased its stake in Qiagen N.V. by 13.7% in the first quarter. Bank of New York Mellon Corp now owns 1,222,959 shares of the company’s stock worth $35,430,000 after buying an additional 147,752 shares in the last quarter. 60.07% of the stock is owned by institutional investors and hedge funds.

Qiagen N.V. (NASDAQ QGEN) opened at 31.54 on Friday. The stock has a market capitalization of $7.20 billion, a PE ratio of 96.45 and a beta of 1.14. Qiagen N.V. has a 52-week low of $24.89 and a 52-week high of $35.26. The company’s 50-day moving average price is $32.76 and its 200 day moving average price is $31.36.

Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. The business had revenue of $349 million during the quarter, compared to the consensus estimate of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Equities analysts forecast that Qiagen N.V. will post $1.22 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/27/rhumbline-advisers-purchases-9208-shares-of-qiagen-n-v-qgen.html.

Several equities analysts have recently weighed in on the company. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research report on Friday, June 23rd. TheStreet upgraded Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen N.V. in a research report on Monday, July 24th. Bank of America Corporation reiterated a “neutral” rating and issued a $36.00 price target (up from $33.00) on shares of Qiagen N.V. in a research report on Friday, July 21st. Finally, Barclays PLC reiterated an “overweight” rating and issued a $37.00 price target (up from $33.00) on shares of Qiagen N.V. in a research report on Monday, July 17th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $33.17.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.